These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10906626)

  • 1. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.
    Feldman R
    Can J Cardiol; 2000 Aug; 16 Suppl E():41E-44E. PubMed ID: 10906626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of ACE inhibitors versus AT1 blockers.
    Vaughan D
    Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [AT1 angiotensin receptor inhibition as a new therapeutic possibility].
    Hunyady L; Nagy L
    Orv Hetil; 1997 Oct; 138(41):2583-90. PubMed ID: 9411327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.
    Yavuz D; Koç M; Toprak A; Akpinar I; Velioğlu A; Deyneli O; Haklar G; Akalin S
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):197-203. PubMed ID: 14608527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effect of angiotensin II receptor antagonists.
    White M
    Can J Cardiol; 1999 Nov; 15 Suppl F():10F-4F. PubMed ID: 10579747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
    Hedner T
    J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Angiotensin II AT1 receptor antagonists: clinical development and future perspectives].
    Burnier M; Brunner HR
    Therapie; 1998; 53(3):279-84. PubMed ID: 9773127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Concurrence to ACE inhibitors? AT1 receptor blockers and hypertension].
    Heemann U; Kribben A; Phillip T
    Pharm Unserer Zeit; 2001; 30(4):309-12. PubMed ID: 11499256
    [No Abstract]   [Full Text] [Related]  

  • 11. [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
    Hauser AC; Hörl WH
    Wien Med Wochenschr; 2001; 151(7-8):160-4. PubMed ID: 11450164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Converting enzyme inhibitors or AT1 receptor blockers].
    Trevethan Cravioto S
    Arch Cardiol Mex; 2001; 71 Suppl 1():S171-6. PubMed ID: 11565329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
    Fournier A; Oprisiu-Fournier R; Serot JM; Godefroy O; Achard JM; Faure S; Mazouz H; Temmar M; Albu A; Bordet R; Hanon O; Gueyffier F; Wang J; Black S; Sato N
    Expert Rev Neurother; 2009 Sep; 9(9):1413-31. PubMed ID: 19769454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renin-angiotensin system and cardiovascular disease.
    Hollenberg NK
    Blood Press Suppl; 2000; 1():5-8. PubMed ID: 11059628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
    Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
    J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
    Flammer AJ; Hermann F; Wiesli P; Schwegler B; Chenevard R; Hürlimann D; Sudano I; Gay S; Neidhart M; Riesen W; Ruschitzka F; Lüscher TF; Noll G; Lehmann R
    J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.